Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 11/20 | 0.66 |
| ▸ | IKBKB | O14920 | 1/20 | 0.66 |
| ▸ | MARK3 | P27448 | 2/20 | 0.48 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.48 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.48 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 5/20 | 0.44 |
| ▸ | JAK3 | P52333 | 4/20 | 0.41 |
| ▸ | MET | P08581 | 2/20 | 0.41 |
| ▸ | JAK1 | P23458 | 3/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4886321 | 0.88 | CHEK1 (0.63) | CHEK1IKBKBMARK3MARK2AURKB | |
| SCHEMBL4888868 | 0.84 | CHEK1 (0.72) | CHEK1IKBKBMARK3MARK2AURKB | |
| SCHEMBL4849487 | 0.83 | CHEK1 (0.64) | CHEK1IKBKBMARK3MARK2AURKB | |
| SCHEMBL5450351 | 0.83 | CHEK1 (0.63) | CHEK1IKBKBMARK3MARK2AURKB | |
| SCHEMBL4891936 | 0.82 | CHEK1 (0.65) | CHEK1IKBKBMARK3MARK2AURKB | |
| SCHEMBL4881049 | 0.81 | CHEK1 (0.71) | CHEK1IKBKBMARK3MARK2AURKB | |
| SCHEMBL4882434 | 0.80 | CHEK1 (0.84) | CHEK1IKBKBMARK3MARK2AURKB | |
| SCHEMBL4883979 | 0.79 | CHEK1 (0.61) | CHEK1IKBKBMARK3MARK2AURKB | |
| SCHEMBL4889204 | 0.78 | CHEK1 (0.80) | CHEK1IKBKBMARK3MARK2AURKB | |
| SCHEMBL4880052 | 0.78 | CHEK1 (1.00) | CHEK1IKBKBMARK3MARK2AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1606268-B1 | 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS | ABBVIE INC (US) | 2015-05-20 | — | — | EP | claimed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | claimed |
| EP-1606268-A1 | HETEROCYCLIC KINASE INHIBITORS | Abbott Laboratories (US) | 2005-12-21 | — | — | EP | claimed |
| US-20040254159-A1 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES | 2004-12-16 | — | — | US | claimed |
| WO-2004076424-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-10 | — | — | WO | claimed |
| EP-1606268-B1 | 5,10-DIHYDRO-11H-DIBENZO[B,E][1,4]DIAZEPIN-11-ONE AS KINASE INHIBITORS | ABBVIE INC (US) | 2015-05-20 | — | — | EP | disclosed |
| US-7456169-B2 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | ABBVIE INC. | 2007-11-01 | — | — | US | disclosed |
| US-20040254159-A1 | Heterocyclic kinase inhibitors | ABBOTT LABORATORIES | 2004-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254159-A1 | Heterocyclic kinase inhibitors | MAP3K20, MAP3K19, MAP3K1 | CHEK1 46/4885IKBKB 421/4885MARK3 466/4885 |
| US-20070254867-A1 | Heterocyclic Kinase Inhibitors | MAP3K20, MAP3K19, MAP4K2 | CHEK1 38/4885IKBKB 358/4885MARK3 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.